News
01 April 2021
EU
Asthma , Allergy

Through ImmUniverse, EFA is involved in research aiming to improve diagnostic and therapeutic options for patients living with immune-mediated inflammatory diseases, including atopic eczema. EFA coordinates a Patient Input Platform (PIP) to ensure the project achieves a patient-centred focus.

On 26-27th January 2021, ImmUniverse held its first annual meeting after the kick-off one year ago. The progress of the project is evolving despite being affected by the COVID-19 pandemic. This has led to limited involvement of the PIP within the research activities during the first year.

Meanwhile, as a member of the Communications Committee of ImmUniverse EFA supported the development of communication materials of the project, ensuring the production of patient-friendly outcomes. This included reviewing the content and structure of the project’s website and promotional video.  

More information on the project can be found here.

Dear Visitor,

for regularly updated information on Covid-19 for allergy and respiratory patients, please consult our Covid-19 resource and information hub.
Stay safe!
The EFA Team